Literature DB >> 19533590

Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis.

Katja Sobczak1, Andrei Segal, Nadine Bangel-Ruland, Judith Semmler, Willy Van Driessche, Hermann Lindemann, Ralf Heermann, Wolf-Michael Weber.   

Abstract

BACKGROUND: Cystic fibrosis (CF) respiratory epithelia are characterized by a defect Cl(-) secretion and an increased Na(+) absorption through epithelial Na(+) channels (ENaC). The present study aimed to find an effective inhibitor of human ENaC with respect to replacing amiloride therapy for CF patients. Therefore, we developed specific antisense oligonucleotides (AON) that efficiently suppress Na(+) hyperabsorption by inhibiting the expression of the alpha-ENaC subunit.
METHODS: We heterologously expressed ENaC in oocytes of Xenopus laevis for mass screening of AON. Additionally, primary cultures of human nasal epithelia were transfected with AON and were used for Ussing chamber experiments, as well as biochemical and fluorescence optical analyses.
RESULTS: Screening of several AON by co-injection or sequential microinjection of AON and ENaC mRNA in X. laevis oocytes led to a sustained decrease in amiloride-sensitive current and conductance. Using primary cultures of human nasal epithelia, we show that AON effectively suppress amiloride-sensitive Na(+) absorption mediated by ENaC in CF and non-CF tissues. In western blot experiments, it could be shown that the amount of ENaC protein is effectively reduced after AON transfection.
CONCLUSIONS: Our data comprise an initial step towards a preclinical test with AON to reduce Na(+) hyperabsorption in CF epithelia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533590     DOI: 10.1002/jgm.1363

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  4 in total

Review 1.  The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.

Authors:  Ren-Jay Shei; Jacelyn E Peabody; Niroop Kaza; Steven M Rowe
Journal:  Curr Opin Pharmacol       Date:  2018-10-16       Impact factor: 5.547

Review 2.  Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Authors:  Marcus A Mall; Nicole Mayer-Hamblett; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

3.  Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.

Authors:  Kenneth L Clark; Stephen A Hughes; Pallav Bulsara; Jill Coates; Kitty Moores; Joel Parry; Michael Carr; Ruth J Mayer; Paul Wilson; Chris Gruenloh; Daren Levin; Jill Darton; Wolf-Michael Weber; Katja Sobczak; Deborah R Gill; Stephen C Hyde; Lee A Davies; Ian A Pringle; Stephanie G Sumner-Jones; Vasant Jadhav; Sharon Jamison; Walter R Strapps; Victoria Pickering; Mark R Edbrooke
Journal:  Mol Ther Nucleic Acids       Date:  2013-01-15       Impact factor: 10.183

4.  Chitosan Nanocomplexes for the Delivery of ENaC Antisense Oligonucleotides to Airway Epithelial Cells.

Authors:  A Katharina Kolonko; Nadine Bangel-Ruland; Francisco M Goycoolea; Wolf-Michael Weber
Journal:  Biomolecules       Date:  2020-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.